华北制药
(600812)
| 流通市值：80.12亿 | | | 总市值：80.12亿 |
| 流通股本：17.16亿 | | | 总股本：17.16亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 6,009,539,891.23 | 4,219,592,946.76 | 2,153,167,876.49 | 9,241,652,953.8 |
| 营业收入 | 6,009,539,891.23 | 4,219,592,946.76 | 2,153,167,876.49 | 9,241,652,953.8 |
| 二、营业总成本 | 5,944,803,195.83 | 4,139,210,250.29 | 2,088,645,071.89 | 8,957,348,085.02 |
| 营业成本 | 4,430,461,247.08 | 3,078,480,910.11 | 1,529,816,825.63 | 6,376,291,487.83 |
| 税金及附加 | 78,718,457.31 | 54,429,939.76 | 28,033,926.51 | 108,781,473.4 |
| 销售费用 | 566,009,419.42 | 403,015,239.91 | 221,664,872.41 | 1,231,089,983.18 |
| 管理费用 | 364,077,145.26 | 258,691,172.73 | 132,557,417.81 | 554,117,130.38 |
| 研发费用 | 267,222,872.14 | 180,768,211 | 95,623,753.58 | 340,998,836.39 |
| 财务费用 | 238,314,054.62 | 163,824,776.78 | 80,948,275.95 | 346,069,173.84 |
| 其中:利息费用 | 231,157,618.41 | 151,511,629.14 | 74,988,313.19 | 361,548,158.82 |
| 其中:利息收入 | 22,019,170.88 | 10,026,957.82 | 4,623,296.58 | 25,816,694.2 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | 58,337,512.75 | 31,632,214.99 | 14,639,070.57 | 60,625,000.37 |
| 资产处置收益 | 817,347.36 | 217,802.15 | 20,894.61 | 827,335.68 |
| 资产减值损失(新) | 6,746,984.38 | 6,650,965.62 | -265,870.11 | 17,226,881.24 |
| 信用减值损失(新) | -12,210,453.53 | -10,983,441.41 | -17,576,736.4 | -44,196,286.29 |
| 其他收益 | 26,185,425.76 | 16,490,640.12 | 5,234,624.23 | 35,183,803.6 |
| 四、营业利润 | 144,613,512.12 | 124,390,877.94 | 66,574,787.5 | 353,971,603.38 |
| 加:营业外收入 | 7,192,838.78 | 1,081,066.23 | 59,589.24 | 4,953,011.43 |
| 减:营业外支出 | 2,518,271.03 | 1,541,473 | 353,172.97 | 1,515,666.77 |
| 五、利润总额 | 149,288,079.87 | 123,930,471.17 | 66,281,203.77 | 357,408,948.04 |
| 减:所得税费用 | 48,407,642.58 | 33,057,923.62 | 16,904,320.58 | 99,955,846.2 |
| 六、净利润 | 100,880,437.29 | 90,872,547.55 | 49,376,883.19 | 257,453,101.84 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 100,880,437.29 | 90,872,547.55 | 49,376,883.19 | 257,453,101.84 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 64,891,710.13 | 63,845,928.44 | 35,472,827.49 | 183,056,160.84 |
| 少数股东损益 | 35,988,727.16 | 27,026,619.11 | 13,904,055.7 | 74,396,941 |
| 扣除非经常损益后的净利润 | 39,386,535.05 | 58,575,911.72 | 32,264,176.51 | 165,918,468.01 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.04 | 0.04 | 0.02 | 0.11 |
| (二)稀释每股收益 | 0.04 | 0.04 | 0.02 | 0.11 |
| 八、其他综合收益 | -3,696,057.55 | -2,909,537.26 | -1,662,299.38 | -14,247,723.02 |
| 归属于母公司股东的其他综合收益 | -3,696,057.55 | -2,909,537.26 | -1,662,299.38 | -14,247,723.02 |
| 九、综合收益总额 | 97,184,379.74 | 87,963,010.29 | 47,714,583.81 | 243,205,378.82 |
| 归属于母公司股东的综合收益总额 | 61,195,652.58 | 60,936,391.18 | 33,810,528.11 | 168,808,437.82 |
| 归属于少数股东的综合收益总额 | 35,988,727.16 | 27,026,619.11 | 13,904,055.7 | 74,396,941 |
| 公告日期 | 2026-10-28 | 2026-08-22 | 2026-04-25 | 2026-04-18 |
| 审计意见(境内) | | | | 标准无保留意见 |